ESMO 2019 | Rucaparib maintenance for recurrent ovarian carcinoma

Name: Rucaparib maintenance for recurrent ovarian carcinoma
Uploaded: 2019-09-30T00:00:00Z
Duration: 2 min 9 s
Description: Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses the use of rucaparib for the maintenance treatment of recurrent ovarian carcinoma, specifically highlighting data from the Phase III ARIEL3 trial (NCT01968213). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Jonathan Ledermann • 30 Sep 2019

ESMO 2019

Ovarian Cancer Rucaparib

ARIEL3

Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses the use of rucaparib for the maintenance treatment of recurrent ovarian carcinoma, specifically highlighting data from the Phase III ARIEL3 trial (NCT01968213). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.